,45 Although drugs targeting DLL3 are currently administered to metastatic SCLC patients irrespective of their DLL3 expression status, investigation of patient-specific DLL3 expression might change current clinical practices in the years to come. Here, DLL3 is linked to small cell lung carcinoma.